Wilms tumor 1 (WT1) is overexpressed in many human cancers, including glioblastoma multiforme (GBM). In another study, the authors showed that transient WT1 silencing increases the radiosensitivity of glioma cells. Studies of nonglioma cell lines have demonstrated that WT1 promotes cell proliferation and survival; however, this ability has not been rigorously analyzed in human GBM.
The authors tested the efficacy of 2 sequences of short hairpin RNA (shRNA) directed against WT1 in U251MG human GBM cells and found that 1 sequence was capable of stably silencing WT1 expression. They then evaluated the effect of WT1 silencing on cellular proliferation, invasion, and in vivo tumor formation.
Stable WT1-shRNA expression significantly decreased the proliferation of U251MG cells in vitro as demonstrated by both an adenosine 5′-triphosphate–based viability assay and tritiated thymidine uptake. Furthermore, stable WT1 silencing caused significantly slower growth after the subcutaneous inoculation of tumor cells in the flanks of athymic nude mice and was associated with an increased latency period.
Data in this study provide proof of the principle that downregulation of WT1 causes decreased tumorigenicity of a GBM cell line in vitro and in vivo and suggest that WT1 is a promising target for novel molecular GBM therapies, perhaps in combination with standard treatment modalities.
Abbreviations used in this paper: ANOVA = analysis of variance; ATP = adenosine 5′-triphosphate; GBM = glioblastoma multiforme; GFP = green fluorescent protein; PBS = phosphate-buffered saline; SDS = sodium dodecyl sulfate; shRNA = short hairpin RNA; WT1 = Wilms tumor 1; [3H]Td = tritiated thymidine.
Central Brain Tumor Registry of the United States: Primary Brain Tumors in the United States Statistical Reports 1998–2002Hinsdale, ILCentral Brain Tumor Registry of the United States2006. (http://www.cbtrus.org/reports//2005-2006/2006report.pdf) [Accessed 11 November 2008]
GianniniCSarkariaJNSaitoAUhmJHGalanisECarlsonBL: Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro Oncol7:164–1762005
LiuXWGongLJGuoLYKatagiriYJiangHWangZY: The Wilms' tumor gene product WT1 mediates the downregulation of the rat epidermal growth factor receptor by nerve growth factor in PC12 cells. J Biol Chem276:5068–50732001
MenkeALRitecoNvan HamRCde BruyneCRauscherFJIIIvan der EbAJ: Wilms' tumor 1 splice variants have opposite effects on the tumorigenicity of adenovirus-transformed baby-rat kidney cells. Oncogene12:537–5461996
MenssenHDBertelmannEBarteltSSchmidtRAPecherGSchrammK: Wilms' tumor gene (WT1) expression in lung cancer, colon cancer and glioblastoma cell lines compared to freshly isolated tumor specimens. J Cancer Res Clin Oncol126:226–2322000
SarkariaJNCarlsonBLSchroederMAGroganPBrownPDGianniniC: Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin Cancer Res12:2264–22712006